Cancer genomics: The challenge of drug accessibility

Current Opinion in Oncology

Volumn 27, Issue 3, 2015, Pages 250-257

  Lewin, Jeremy ^a   Siu, Lillian L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

cancer; drug access; drug development; genomics; personalized medicine

Indexed keywords

ABIRATERONE; AXITINIB; BOSUTINIB; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; DOCETAXEL; ENZALUTAMIDE; EVEROLIMUS; HOMOHARRINGTONINE; IMATINIB; IPILIMUMAB; PAZOPANIB; PONATINIB; REGORAFENIB; SUNITINIB; TRASTUZUMAB; VANDETANIB; VEMURAFENIB; VISMODEGIB; ANTINEOPLASTIC AGENT;

CANCER GENETICS; CLINICAL TRIAL (TOPIC); COMPASSIONATE USE; DRUG APPROVAL; DRUG COST; DRUG DEVELOPMENT; FUNDING; GENE MUTATION; GENOMICS; HUMAN; MOLECULARLY TARGETED THERAPY; OFF LABEL DRUG USE; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STUDY DESIGN; CANCER CENTER; CLINICAL PRACTICE; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; NEOPLASMS; PRACTICE GUIDELINE; PRESCRIPTION; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION;

ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; DRUG APPROVAL; DRUG PRESCRIPTIONS; EVIDENCE-BASED MEDICINE; HEALTH SERVICES ACCESSIBILITY; HUMANS; NEOPLASMS; OFF-LABEL USE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS';

EID: 84928478493     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000185     Document Type: Review

References (55)

1. Von Hoff DD, Stephenson JJ, Rosen P, et al. Pilot study using molecular profiling of patients tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28:4877-4883.
2. Tsimberidou A-M, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center Initiative. Clin Cancer Res 2012; 18:6373-6383.
3. Dienstmann R, Serpico D, Rodon J, et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther 2012; 11:2062-2071.
4. Bedard P, Oza A, Tsao M, et al. Princess Margaret Cancer Centre integrated molecular profiling in advanced cancers trial (IMPACT) using genotyping and targeted next-generation sequencing. J Clin Oncol 2013; 31:11002.
5. Ferté C, Massard C, Ileana E, et al. Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; interim analysis of 420 patients. Cancer Res 2014; 74:CT240.
6. André F, Bachelot T, Commo F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014; 15:267-274.
7. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014; 20:682-688.
8. Good BM, Ainscough BJ, McMichael JF, et al. Organizing knowledge to enable personalization of medicine in cancer. Gen Biol 2014; 15:438.
9. Andre F, Mardis E, Salm M, et al. Prioritizing targets for precision cancer medicine. Ann Oncol 2014; 25:2295-2303.
10. Swanton C. SAFIR01: steps towards precision treatment in breast cancer. Lancet Oncol 2014; 15:242-243.
11. McMillin DW, Negri JM, Mitsiades CS. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 2013; 12:217-228.
12. Gray SW, Hicks-Courant K, Cronin A, et al. Physicians attitudes about multiplex tumor genomic testing. J Clin Oncol 2014; 32:1317-1323.
13. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3:111ra21.
14. Foundation Medicine1. Available from: http://investors.foundationmedicine. com/releasedetail.cfm?ReleaseID=879740. [Accessed 11 November 2014]
15. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013; 12:358-369.
16. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011; 17:297-303.
17. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
18. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
19. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009; 6:259-265.
20. Hollebecque A, Postel-Vinay S, Verweij J, et al. Modifying phase I methodology to facilitate enrolment of molecularly selected patients. Eur J Can 2013; 49:1515-1520.
21. Karavasilis V, Digue L, Arkenau T, et al. Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital. Eur J Can 2008; 44:978-982.
22. Ho J, Pond GR, Newman C, et al. Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer 2006; 6:263.
23. TsaoM-S, Sakurada A, Cutz J-C, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-144.
24. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
25. Samuel N, Verma S. Cross-comparison of cancer drug approvals among international regulatory bodies. Ann Oncol 2014; 25 (suppl 4):v1-v41.
26. National Institute for Health and Care Excellence. Crizotinib for previously treated nonsmall-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene. Available from: https://www.nice.org.uk/guidance/ta296. [Accessed 27 October 2014]
27. Cheema P, Gavura S, Migus M, et al. International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol 2012; 19:e165-e176.
28. Smieliauskas F, Chien C-R, Shen C, et al. Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. Pharmacoeconomics 2014; 1-30.
29. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med 2011; 364:2060-2065.
30. American Society of Clinical Oncology. The State of Cancer Care in America, 2014: a report by the American Society of Clinical Oncology. J Oncol Pract 2014; 10:119-142.
31. Conti RM, Bernstein AC, Villaflor VM, et al. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a populationbased cohort of medical oncologists. J Clin Oncol 2013; 31:1134-1139.
32. Krzyzanowska MK. Off-label use of cancer drugs: a benchmark is established. J Clin Oncol 2013; 31:1125-1127.
33. American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol 2006; 24:3206-3208.
34. Johnson PE. Pharmaceutical reimbursement: an overview. Am J Health Syst Pharm 2008; 65 (Suppl 1):S4-S10.
35. Abernethy AP, Raman G, Balk EM, et al. Systematic review: reliability of compendia methods for off-label oncology indications. Ann Int Med 2009; 150:336-343.
36. Bernardi A, Pegoraro R. The ethics of off-label use of drugs: oncology pharmacy in Italy. J Clin Pharm Ther 2008; 33:95-99.
37. Casali P. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 2007; 18:1923-1925.
38. Schilsky RL. Implementing personalized cancer care. Nat Rev Clin Oncol 2014; 11:432-438.
39. Bedard P, Hansen A, Ratain M, Siu L. Tumour heterogeneity in the clinic. Nature 2013; 501:355-364.
40. Papadimitrakopoulou V, Wistuba II, Lee JJ, et al. BATTLE-2 program: a biomarker-integrated targeted therapy study in previously treated patients with advanced nonsmall cell lung cancer (NSCLC). J Clin Oncol 2013; 31: (suppl; abstr TPS8118).
41. NCT02193282. Erlotinib Hydrochloride in Treating Patients With Stage IBIIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial. Available online: http://www.clini caltrials.gov/ct2/show/NCT02193282. [Accessed 27 October 2014]
42. NCT02201992. Crizotinib in Treating Patients With Stage IB-IIIA Nonsmall Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial). Available online: http://www. clinicaltrials.gov/ct2/show/NCT02201992. [Accessed 27 October 2014]
43. NCT02154490. Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer. Available online: http://clinicaltrials.gov/show/NCT02154490. [Accessed 27 October 2014]
44. NCT02117167. Intergroup Trial UNICANCER UC 0105-1305/IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (SAFIR02-Lung). Available online: http://www.clinicaltrials.gov/ct2/show/NCT02117167. [Accessed 21 October 2014]
45. Kaplan R, Maughan T, Crook A, et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol 2013; 31:4562-4568.
46. Barker A, Sigman C, Kelloff G, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86:97-100.
47. NCT02152254. IMPACT 2: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer Available online: http://www.clinicaltrials.gov/ct2/show/NCT02152254. [Accessed 22 October 2014]
48. NCT01827384. NCI-MPACT: Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors. Available online: http://www.clinicaltrials.gov/ct2/show/NCT01827384. [Accessed 21 October 2014]
49. Le Tourneau C, Paoletti X, Servant N, et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs. conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. BJC 2014; 111:17-24.
50. NCI-MATCH. A large phase II master protocol for target-drug matching focusing on both common and rare cancers. Available online: http://deain fo.nci.nih.gov/advisory/ncab/164-1213/Conley.pdf. [Accessed 27 October 2014]
51. NCT01856296. A Study to Select Rational Therapeutics Based on the Analysis of Matched Tumor and Normal Biopsies in Subjects With Advanced Malignancies (WINTHER). Available online: http://www.clinicaltrials.gov/ct2/show/NCT01856296. [Accessed 27 October 2014]
52. NCT01524978. A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers. Available online: http://www.clinicaltrials. gov/ct2/show/NCT01524978. [Accessed 27 October 2014]
53. NCT01524926. CREATE: Cross-tumoral Phase 2 With Crizotinib. Available online: http://www.clinicaltrials.gov/ct2/show/NCT01524926. [Accessed 27 October 2014]
54. Korn EL, Freidlin B. Outcome-adaptive randomization: is it useful? J Clin Oncol 2011; 29:771-776.
55. Ledford H. Clinical drug tests adapted for speed. Nature 2010; 464:1258.